Kun for helsepersonell




Logg innLogg ut
LegemiddelTerapiområdeUtforsk merUtforsk merMateriellVideo/podkastNyhetsbrevKontakt oss



Om ZaviceftaVirkningsmekanismePatogen dekningTidlig hensiktsmessig behandlingIDSA anbefalingØkonomiske holdepunkterSpørsmål og svar om ZAVICEFTAPasientprofilerHAP/VAP pasientcUTI pasientcIAI pasientPediatriske pasienterSpørsmål og svar - FAQsEffekt Real-world evidenceEffektdataSpørsmål og svar om effektSikkerhetSikkerhet hos voksneSikkerhet hos barn/ungdomSpørsmål og svar om sikkerhetDoseringDosering hos voksneDosering hos barn/ungdomSpørsmål og svar om dosering
Tidlig hensiktsmessig antibiotikabehandling er avgjørende for pasienter med alvorlige gramnegative infeksjoner1

Failure to treat early and appropriately can lead to fatal outcomes for these patients.1,2* The impact of delayed appropriate therapy is depicted below:

Impact of delayed appropriate therapy
Scroll left to view table
Delayed appropriate therapy for Gram-negative infections has been associated with poor outcomes.1Listen to Professor Matteo Bassetti discuss practical considerations for early treatment with ZAVICEFTA

The importance of early appropriate therapy in serious infections


P. aeruginosa


With the introduction of ZAVICEFTA and more patients receiving appropriate early treatment, hospital bed days and overall hospitalisation costs are expected to reduce.11-14¶¶Learn about the importance of early appropriate therapy in serious infections with Professor Jean-François Timsit
Footnotes:*Early treatment must consider patient risk factors as well as local epidemiology.1
Compared with receipt of timely appropriate therapy.1
Defined as no receipt of antibiotic(s) with relevant microbiological activity on or within 2 days of index date.1
§28-day mortality among 205 patients with BSIs caused by carbapenemase-producing K. pneumoniae (KPC and/or VIM).3
The epidemiological staging system for measuring the extent of CRE spread across healthcare facilities was developed in 2010.4
**National experts representing all 37 invited European countries completed the 2018 capacity survey.4
††30-day mortality rate among patients with P. aeruginosa bacteraemia who received ‘delayed effective antimicrobial therapy’.6
‡‡Combined resistance to ≥3 of the following: piperacillin/tazobactam, fluoroquinolones, ceftazidime, aminoglycosides and carbapenems.9
§§30-day mortality among 909 patients with BSIs caused by ESBL-producing K. pneumoniae (n=222) and E. coli (n=687).8
¶¶Based on four patient-level simulation models used to evaluate the cost-effectiveness of adding ZAVICEFTA as a treatment for cIAI, cUTI and HAP/VAP to a hospital formulary in Italy. The model and results may vary between markets.11–13
Abbreviations:BSI, bloodstream infections; CRE, carbapenem-resistant Enterobacterales; CPE, carbapenemase-producing Enterobacterales; ESBL, extended-spectrum β-lactamase; KPC, Klebsiella pneumoniae carbapenemase; MDR multidrug resistant.References:Bonine NG, et al. Am J Med Sci 2019;357:102–10.Raman G, et al. BMC Infect Dis 2015;15:395.Daikos GL, et al. Antimicrob Agents Chemother 2014;58:2322–8.Brolund A, et al. Euro Surveill 2019;24:1900123.Bassetti M, et al. Drugs Context 2018;7:212527.Kang CI, et al. Clin Infect Dis 2003;37:745–51.ECDC. Surveillance atlas of infectious diseases 2020 – P. aeruginosa. Available at: https://atlas.ecdc.europa.eu/public/index.aspx (last accessed June 2022).Scheuherman O, et al. Infect Control Hosp Epidemiol 2018;39:660–7.ECDC. Surveillance atlas of infectious diseases 2020 – third generation cephalosporin-resistant K. pneumoniae.ECDC. Surveillance atlas of infectious diseases 2020 – third generation cephalosporin-resistant E. coli. Available at: https://atlas.ecdc.europa.eu/public/index.aspx (last accessed June 2022). Kongnakorn T, et al. Antimicrob Resist Infect Control 2019;8:204.Kongnakorn T, et al. Int J Antimicrob Agents 2019;54:633–41.Tichy E, et al. Clin Ther 2020;42:802–17.Kongnakorn T, et al. Presented IPSOR Europe 2017, 4–8 November 2017, Glasgow, Scotland.
PP-ZVA-NOR-0141 Mai 2023

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00

PP-BCP-NOR-0001 juni 2023

Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.



Du forlater nå PfizerPro.no
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Kun for helsepersonell

Dette nettstedet er kun for helsepersonell.

Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.

Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.

Ja Nei